Breast Cancer: Recurrent Genomic Alterations: Difference between revisions
mNo edit summary |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 76: | Line 76: | ||
'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [ | '''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics. | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Gene(s)''' | |'''Gene(s)''' | ||
| Line 93: | Line 93: | ||
|PARP inhibitors (germline) | |PARP inhibitors (germline) | ||
|- | |- | ||
|''[[ | |''[[BRCA1]], [[BRCA2]]'' | ||
|1 | |1 | ||
|Often hereditary risk; TNBC | |Often hereditary risk; TNBC | ||
| Line 260: | Line 260: | ||
'''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [ | '''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics. | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Gene''' | |'''Gene''' | ||
| Line 271: | Line 271: | ||
|TNBC | |TNBC | ||
|- | |- | ||
|''BRCA1'' | |''[[BRCA1]]'' | ||
|[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | |[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | ||
|- | |- | ||
|''BRCA2'' | |''[[BRCA2]]'' | ||
|[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | |[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC | ||
|- | |- | ||